Avicanna Announces Results of Annual General and Special Meeting
01 Septembre 2022 - 1:30PM
Avicanna Inc. (“
Avicanna” or the
“
Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN),
a commercial stage, international biopharmaceutical company focused
on the commercialization of evidence-based, cannabinoid-based
products, is pleased to announce that all of management’s nominees
listed in the Company’s management information circular dated July
28, 2022 (the “
Circular”) were elected as
directors of the Company at Avicanna’s annual general and special
meeting of shareholders held on August 31, 2022 (the
“
Meeting”).
The detailed results of the vote for the
election of directors held at the Meeting are set out below.
Name of Nominee |
Votes cast FOR |
% votes castFOR |
VotesWITHHELD |
% votesWITHHELD |
Dr. Chandrakant Panchal |
12,443,199 |
99.58% |
52,408 |
0.42% |
ArasAzadian |
12,461,654 |
99.73% |
33,953 |
0.27% |
Giancarlo Davila Char |
12,471,654 |
99.81% |
23,953 |
0.19% |
Eileen McCormack |
12,476,375 |
99.85% |
19,232 |
0.15% |
John McVicar |
12,473,154 |
99.82% |
22,453 |
0.18% |
At the Meeting, the Company’s shareholders also
approved: (i) fixing the number of directors for the ensuing year
at five and empowering the board of directors of the Company to
adjust such number between shareholder meetings by way of
resolution in accordance with the Company’s constating documents;
(ii) the reappointment of Kingston Ross Pasnak LLP as the Company’s
auditors for the ensuing year and authorized the board of directors
to fix the auditors’ remuneration; and (iii) the unallocated awards
under the omnibus long-term incentive plan of the Company.
Assad Kazeminy, PhD voluntarily retiring as a
director did not stand for election.
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of evidence-based cannabinoid-based products for
the global medical and pharmaceutical market segments. Avicanna has
an established scientific platform including R&D and clinical
development that has led to the commercialization of more than
thirty products across various market segments:
Medical Cannabis & Wellness Products:
Marketed under the RHO Phyto™ brand these medical and wellness
products are a line of pharmaceutical-grade cannabinoid products
containing varying ratios of cannabidiol (“CBD”) and
tetrahydrocannabinol (“THC”). The product portfolio contains a full
formulary of products including oral, sublingual, topical, and
transdermal deliveries that have controlled dosing, enhanced
absorption and stability studies supported by pre-clinical data.
The formulary is marketed with consumer, patient and
medical-community education and training.
Pharmaceutical Pipeline: Leveraging Avicanna’s
scientific platform, vertical integration, and real-world evidence,
Avicanna has created a pipeline of patent-pending drug candidates
that are indication-specific and in various stages of clinical
development and commercialization. These cannabinoid-based drug
candidates look to address unmet medical needs in the areas of
dermatology, chronic pain, and various neurological disorders.
Avicanna’s first pharmaceutical preparation (Trunerox™) is in the
drug registration stage in South America.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit
www.avicanna.com, contact Ivana Maric by email at info@avicanna.com
or follow us on social media on LinkedIn, Twitter, Facebook or
Instagram.
The Company posts updates through videos from
the official Company YouTube channel.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified by the use of words such as, “may”, “would”, “could”,
“will”, “likely”, “expect”, “anticipate”, “believe, “intend”,
“plan”, “forecast”, “project”, “estimate”, “outlook” and other
similar expressions. Forward-looking information contained in this
news release includes, without limitation, statements related to
Canadian commercialization efforts, international
commercialization, R&D, financials, statements with respect to
the Company’s future business operations, the opinions or beliefs
of management and future business goals. Although the Company
believes that the expectations and assumptions on which such
forward looking information is based are reasonable, undue reliance
should not be placed on the forward-looking information because the
Company can give no assurance that they will prove to be correct.
Actual results and developments may differ materially from those
contemplated by these statements. Forward-looking information is
subject to a variety of risks and uncertainties that could cause
actual events or results to differ materially from those projected
in the forward-looking information. Such risks and uncertainties
include, but are not limited to current and future market
conditions, including the market price of the common shares of the
Company, and the risk factors set out in the Company’s annual
information form dated March 31, 2022 filed with the Canadian
securities regulators and available under the Company’s profile on
SEDAR at www.sedar.com. The statements in this news release are
made as of the date of this release. The Company disclaims any
intent or obligation to update any forward-looking information,
whether as a result of new information, future events or results or
otherwise, other than as required by applicable securities
laws.
Avicanna (TSX:AVCN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Avicanna (TSX:AVCN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024